ADC Therapeutics (NYSE:ADCT) Posts Quarterly Earnings Results, Beats Estimates By $0.28 EPS

ADC Therapeutics (NYSE:ADCT) announced its earnings results on Tuesday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.28, Zacks reports. The firm had revenue of $23.06 million for the quarter, compared to the consensus estimate of $22.29 million.

Here are the key takeaways from ADC Therapeutics’ conference call:

• The company has refocused on ZYNLONTA lifecycle management, cut operating costs by ~50%, upgraded leadership, and strengthened the balance sheet (cash $261M) with a stated runway into 2028.
• Key clinical catalysts ahead — management expects LOTIS-5 top-line PFS data in Q2 2026, and LOTIS-7 showed a 90% ORR and 78% CR in 49 evaluable patients with enrollment expanded to ~100.
• Commercially, 2025 net product revenues were $73.6M (Q4 $22.3M) with volumes broadly flat and an estimated ~10% share in third-line DLBCL; management expects stability until label expansion.
• Despite reduced expenses and a narrower GAAP loss, the company reported a full-year net loss of $142.6M and future upside depends on regulatory approvals, compendia inclusion and competition from bispecifics, posing execution risk.

ADC Therapeutics Stock Performance

ADCT opened at $4.91 on Thursday. ADC Therapeutics has a 52-week low of $1.05 and a 52-week high of $4.98. The firm has a market cap of $607.74 million, a P/E ratio of -4.09 and a beta of 1.92. The business’s fifty day moving average is $3.92 and its 200-day moving average is $3.88.

Analysts Set New Price Targets

Several analysts recently issued reports on ADCT shares. Weiss Ratings restated a “sell (d-)” rating on shares of ADC Therapeutics in a research note on Wednesday, January 21st. Guggenheim reissued a “buy” rating and set a $10.00 target price on shares of ADC Therapeutics in a report on Wednesday, November 12th. Wall Street Zen raised shares of ADC Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $5.00 price target on shares of ADC Therapeutics in a research report on Wednesday, December 3rd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Institutional Investors Weigh In On ADC Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ADCT. Engineers Gate Manager LP acquired a new stake in ADC Therapeutics during the fourth quarter worth about $43,000. Creative Planning bought a new stake in shares of ADC Therapeutics during the 2nd quarter worth approximately $96,000. Russell Investments Group Ltd. lifted its holdings in shares of ADC Therapeutics by 31.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 32,502 shares of the company’s stock worth $130,000 after acquiring an additional 7,701 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of ADC Therapeutics by 25.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,750 shares of the company’s stock worth $166,000 after acquiring an additional 9,537 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its position in shares of ADC Therapeutics by 65.3% during the 4th quarter. MetLife Investment Management LLC now owns 49,682 shares of the company’s stock worth $175,000 after acquiring an additional 19,633 shares in the last quarter. Institutional investors own 41.10% of the company’s stock.

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.